Expert Opinion on Orphan Drugs

Expert Opinion on Orphan Drugs 由 Taylor and Francis Ltd. 出版。按 OpenAlex 近年发文统计，该刊主要发表 Lysosomal Storage Disorders Research、Genomics and Rare Diseases、Health Systems, Economic Evaluations, Quality of Life 等主题的论文，这 3 个主题约占 19%，主导子领域为 Genetics、Economics and Econometrics。（根据 OpenAlex 主题统计与中科院分区数据生成）

This title has ceased (2024). Expert Opinion on Orphan Drugs [e-ISSN 2167-8707] is an international journal publishing rigorously peer-reviewed review articles and original papers on rare diseases and orphan drugs. Each article is structured to incorporate the author’s own expert opinion on the impact of the topic on research and clinical practice and the scope for future development. Expert Opinion on Orphan Drugs aims to draw a spotlight on diseases that do not have a high prevalence but have a huge impact on patients and their clinicians, through valuable and high-quality expert insights. In a field which is ever-growing and changing, Expert Opinion on Orphan Drugs is committed to acting as a reliable beacon of guidance and support for researchers, clinicians, patients and advocacy groups in order to optimise research, development, management and quality of life of rare disease patients. Articles focus on the following key areas: Diagnostics, pharmacogenomics and screening; Public health and epidemiology; Drug development; Lead generation and discovery; Early or late phase clinical trials; Regulatory issues; Post-marketing safety and treatment outcomes. The journal also welcomes solicited and unsolicited papers including Drug Evaluations, specifically reviewing the pharmacological properties, clinical potential/clinical efficacy, safety and, if applicable, HE/OR data on a particular orphan drug, as well as Original Research papers and Editorials. Once your paper has been assessed for suitability by the Editorial Team, it will then be double-anonymous peer-reviewed by independent, expert referees. *Please note that Expert Opinion on Orphan Drugs converted to a full Open Access journal from Volume 11 (2023). Previous volumes will continue to provide access through a Pay to Read model. From 2023 the Print ISSN is not in active use as this journal is no longer published in print. Sorry, there are currently no metrics available for this journal.

摘自期刊官网 Aims & Scope

研究方向（LetPub）：PHARMACOLOGY & PHARMACY

中科院期刊分区表

数据库收录

ScopusLetPub

国际期刊预警名单：各版本均未列入LetPub

不同版本、大类与小类分别展示，不将不同评价口径合并为一个分区值；投稿与考核前请确认所在机构采用的版本。

影响力指标

影响因子

5.13LetPub · 2026-09-13

CiteScore 2026-06

2.3LetPub · 2026-09-13

SJR 2026-06

0.2LetPub · 2026-09-13

SNIP 2026-06

0.29LetPub · 2026-09-13

h-index

13LetPub · 2026-09-13

h-index

34OpenAlex · 2026-10-01

i10-index

148OpenAlex · 2026-10-01

两年平均被引

14.4OpenAlex · 2026-10-01

Gold OA 文章占比

30.77%LetPub · 2026-09-13

发文规模

年文章数

3LetPub · 2026-09-13

不同来源的统计口径与观测时间不同，页面保留各来源原值；“出版商公布”为期刊官网自述数据。

评审方式

双盲同行评审出版商官网

社区反馈来自投稿者样本，置信度 0.5，不代表期刊承诺；“出版商公布”的时间节点定义以官网为准。

混合期刊的文章处理费仅在作者选择开放获取发表时收取；按订阅方式发表通常不收费。

费用以期刊官网为准；不同来源的观测时间可能不同，页面保留各来源原值，不做平均。

摘录来自期刊官网页面，仅保留原文片段；“模型摘要”由 Workers AI 生成并经原文校验，以官网为准。

出版商

Taylor and Francis Ltd.

出版国家或地区

ENGLAND

出版语言

English

ISSN

2167-8707

官网最新一期

Volume 12, Issue 1（2024 年）

官方链接

• 期刊主页 ↗OpenAlex
• 投稿系统 ↗LetPub
• 专刊 / 特刊征稿 ↗出版商官网